Teva Pharma (TEVA) Tops Q3 EPS by 3c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.69, $0.03 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.14 billion.
GUIDANCE:
Teva Pharma sees FY2024 EPS of $2.40-$2.50, versus the consensus of $2.45. Teva Pharma sees FY2024 revenue of $16.1-16.5 billion, versus the consensus of $16.262 billion.
For earnings history and earnings-related data on Teva Pharma (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) call put ratio 2.7 calls to 1 put into quarter results
- CoreWeave shares slip despite CrowdStrike partnership
- American Express expands NBA and WNBA partnership to global markets
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
